Table 5 Survival of pancreatic cancer patients treated with tomotherapy and concurrent capecitabine
From: Helical tomotherapy with concurrent capecitabine for the treatment of inoperable pancreatic cancer
Group | Characteristics | Median duration of survival (months) |
|---|---|---|
I | Locally advanced without metastasis (n = 10) | 9.25 (2.00-18.4) |
|  |    No previous chemotherapy (n = 8) | 12.55 (6.50-18.4) |
|  |    Previous chemotherapy (n = 2) | 3.90 (2.00, 5.8) |
II | Locally relapsed without metastasis following complete resection (n = 1) | 4.80 (4.80) |
III | Metastatic disease (n = 8) | 4.25 (1.10-21.00) |
|  |    De novo (n = 3) | 4.40 (3.90-6.50) |
|  |    Relapsed (n = 5) | 4.10 (1.10-21.00) |